Xoft Signs Sales Development Agreement W...( FREMONT Calif. Jan. 29 /- Xoft In...),Health

FREMONT, Calif., Jan. 29 /PRNewswire/ -- Xoft, Inc., developer of the Axxent(R) Electronic Brachytherapy System, and Elekta, a global leader in radiation oncology and non-invasive neurosurgery solutions, announced that the companies have signed a sales development agreement.

Under the agreement, Elekta will share identified sales opportunities for the Xoft Axxent Electronic Brachytherapy in the radiation oncology market. This non-exclusive agreement allows Elekta to expand its revenue to include procedures performed outside shielded rooms by partially sharing in revenues Xoft receives from the sale of the Electronic Brachytherapy controller. Additionally, the companies will explore other areas of collaboration, which could include international sales and joint development agreements.

"We are pleased to enter a sales and marketing agreement with Elekta, a recognized leader and technology innovator in radiation oncology," said Michael Klein, president and CEO of Xoft. "This represents a true win-win situation for both companies: The Axxent Electronic Brachytherapy System rounds out Elekta's product offering with an innovative new method of delivering partial breast irradiation in minimally shielded rooms, giving sites the ability to maximize availability of their vaults for procedures that can only be performed in shielded rooms. For Xoft, Elekta's strong radiation oncology presence and market share offers tremendous visibility and the ability to dramatically expand access to this important new treatment option.

"Xoft's expansion into new treatment areas, which are pending FDA clearance, will extend the use of the electronic brachytherapy to endometrial and rectal indications and therefore allow for broader sales opportunities working with Elekta."

Designed to deliver localized non-radioactive radiation treatment directly to cancer sites, the proprietary Axxent treatment platform can be used in virtually any clinical setting under th
'/>"/>